

2024 年度 業績

論文 (英文)

原著

1. Fujimoto N, Nagata Y, Shiota M, Minato A, Tomisaki I, Harada K, Eto M, Miyamoto H.
The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.
In Vivo. 38: 2328-2334, 2024.
2. Kudo Y, Nakamura K, Tsuzuki H, Hirota K, Kawai M, Takaya D, Fukuzawa K, Honma T, Yoshino Y, Nakamura M, Shiota M, Fujimoto N, Ikari A, Endo S.
Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition.
Archives of Biochemistry and Biophysics 760(2024)110135
3. Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S.
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26.PMID: 38148124
4. Kashiwagi E, Kawahara T, Kinoshita F, Shiota M, Inokuchi J, Miyamoto H, Eto M
The role of adipocytokines and their receptors in prostate cancer: adiponectin may protect against progression
Anticancer Res. 44(4):1369-1376, 2024
5. Kashiwagi E, Hatano T, Shimizu K, Takamoto A, Tomita, K, Osawa T, Sakuhara Y, Hongo F, Hirota T, Ushijima Y, Asayama Y, Goto S, Miki J, Matsukawa A, Kiyomi F, Egawa S, Nasu Y, Shinohara N, Ukimura O, Nakano S, Arai Y, Eto, M.
Safety and efficacy of cryotherapy for the treatment of renal angiomyolipoma related to tuberous sclerosis complex: the cryo-TSC study.
JU Open Plus, 2(6), e00051.2024

6. Tomisaki I, Harada M, Sakano S, Terado M, Hamasuna R, Harada S,
Matsumoto H, Akasaka S, Nagata Y, Minato A, Harada K, Fujimoto N.
Clinical significance of early kinetics of C-reactive protein in patients with advanced
urothelial carcinoma treated with pembrolizumab: Flare response and baseline
levels predict oncological outcomes
Oncol Letters. 28(6). 603, 2024

7. Matsumoto M, Hamasuna R, Wada K, Sadahira T, Shigemura K, Maeda K,
Hiyama Y, Togo Y, Nagasawa S, Yamanaka K, Shigehara K, Kobayashi K,
Tsuchiya H, Miyazaki J, Nakagawa T, Ishikawa K, Takahashi S, Fujimoto N,
Yamamoto S.
Fluoroquinolone resistance and clinical characteristics of acute bacterial prostatitis
in Japan: A multicenter study by the Japanese research group for urinary tract
infection.
Journal of Infection and Chemotherapy. 2024 Aug 14: S1341-321X(24)00221-6. doi:
10.1016/j.jiac.2024.08.012. Online ahead of print.

8. Kobayashi K, Takahashi S, Yasuda M, Miyazaki J, Wada K, Matsumoto M, Hayami
H, Yamamoto S, Kiyota H, Sato J, Matsumoto T, Hasegawa N, Kobayashi I,
Masumori N, Kimura T, Yamada H, Nakagawa T, Kaneko T, Matsumoto K,
Fujimura T, Kamei J, Ishikawa K, Fujimoto K, Nakai Y, Shigemura K, Sadahira T,
Hinata N, Kitano H, Yamashita M, Yasufuku T, Komeda H, Hiyama Y, Takahashi Y,
Kanamaru S, Murakami M, Arakawa S, Yamada D, Mita K, Hamasuna R,
Tanaka K, Matsukawa M, Takaoka E, Shigeta M, Takenaka T, Nishino M,
Ishitoya S, Hayakawa S, Okumura K, Ueda M.
Fourth national Japanese antimicrobial susceptibility pattern surveillance program:
Bacterial isolates from patients with complicated urinary tract infections. Journal of
Infection and Chemotherapy. 2024 Jul;30(7):579-589.

9. Wada K, Tsuboi I, Takahashi S, Yasuda M, Miyazaki J, Kobayashi K, Matsumoto M,
Hayami H, Yamamoto S, Kiyota H, Sato J, Matsumoto T, Hasegawa N, Kobayashi I,
Masumori N, Kimura T, Yamada H, Matsumoto K, Ishikawa K, Fujimoto K,
Shigemura K, Sadahira T, Ito K, Yokoyama T, Izumitani M, Sumii T, Hosobe T,
Hikosaka K, Kawahara M, Sato T, Ito S, Masue N, Sakurai T, Kokura K, Kadena H,
Morikawa T, Minamidate Y, Yoh M, Hashimoto J, Maruyama T, Yoshioka M,
Takashima K, Kawai S, Nishi S, Matsumoto T, Hirayama H, Okusa H, Uno S,
Inoue Y, Kurimura Y, Shirane T, Takaoka E, Tojo T, Arakawa S, Hamasuna R,
Tomioka A, Iihara K, Ishitoya S, Maeda H, Terado M.
Third nationwide surveillance of bacterial pathogens in patients with acute
uncomplicated cystitis conducted by the Japanese surveillance committee during

2020 and 2021: Antimicrobial susceptibility of *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus saprophyticus*.

Journal of Infection and Chemotherapy. 2024 Apr;30(4):277-285.

10. Minato A, Ohno D, Murooka K, Okumura Y, Takaba T, Higashijima K, Nagata Y, Tomisaki I, Harada K, Fujimoto N.
Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
In Vivo. 38: 1927-1934, 2024.
11. Minato A, Murooka K, Okumura Y, Takaba T, Higashijima K, Nagata Y, Tomisaki I, Harada K, Fujimoto N.
Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
In Vivo. 38(2): 873-880, 2024.
12. Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N.
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Curr Oncol. 31(2): 862-871, 2024.
13. Minato A, Furubayashi N, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Tomisaki I, Harada K, Nakamura M, Fujimoto N.
Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: A multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.
Transl Androl Urol 13(7):1118-1126, 2024.
14. Minato A, Furubayashi N, Tomoda T, Masaoka H, Yoohyun S, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Nakamura M, Harada K, Fujimoto N.
Clinical outcomes of enfortumab vedotin in advanced urothelial carcinoma with prior avelumab versus pembrolizumab therapy.
Anticancer Res. 44(8):3419-3426, 2024

15. Minato A, Furubayashi N, Tomoda T, Masaoka H, Yoohyun S, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Organ-specific tumor response to enfortumab vedotin for metastatic urothelial carcinoma: A multicenter retrospective study. Clin Genitourin Cancer. 22(5): 102148, 2024.
16. Minato A, Yoshii M, Watanabe S, Moriya R, Kashiwagi E, Fujimoto N. Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer. Jpn J Clin Oncol. 2024 (in press). DOI: 10.1093/jjco/hyae183
17. Furubayashi N, Minato A, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Harada K, Kuroiwa K, Fujimoto N, Nakamura M. Change in the neutrophil-to-eosinophil ratio after avelumab maintenance for advanced urothelial carcinoma: The UROKYU study. Anticancer Res. 44(4):1675-1681, 2024.
18. Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Yoohyun S, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Cutaneous and renal toxicities of enfortumab vedotin for advanced urothelial carcinoma: The UROKYU study. Anticancer Res. 44(7):3025-3032, 2024.
19. Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Yoohyun S, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Enfortumab vedotin for elderly advanced urothelial carcinoma patients or those with a poor performance status. Anticancer Res. 44(8):3409-3417, 2024.
20. Nagata Y, Minato A, Aono H, Kimuro R, Higashijima K, Tomisaki I, Harada K, Miyamoto H, Fujimoto N. Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Int J Mol Sci. 25: 10348, 2024

21. Nagata Y, Quynh NT, Aono H, Harada K, Miyamoto H, Fujimoto N.
Melatonin Inhibits Chemical Carcinogen-mediated Malignant Transformation of Urothelial Cells: In Vitro Evidence.
Cancer Genomics Proteomics. 21: 388-394, 2024.
22. Nagata Y, Goto T, Teramoto Y, Matsukawa T, Fujimoto N, Miyamoto H.
Mineralocorticoid receptor signaling inhibits bladder cancer progression.
Am J Cancer Res. 14: 696-708, 2024.
23. Goto T, Teramoto Y, Nagata Y, Miyamoto H.
Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression.
Discov Oncol. 15: 440, 2024.
24. Goto T, Yasui M, Teramoto Y, Nagata Y, Mizushima T, Miyamoto H.
Latrophilin-3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis.
Mol Carcinog. 63: 1847-1854, 2024.
25. Himura R, Kawano S, Nagata Y, Kawai M, Ota A, Kudo Y, Yoshino Y, Fujimoto N, Miyamoto H, Endo S, Ikari A.
Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Chem Biol Interact. 388: 110840, 2024.
26. Jojima K, Minato A, Noguchi H, Tsuda Y, Fujimoto N.
Clinical outcomes of micropapillary urothelial carcinoma of the bladder treated with radical cystectomy.
Cancer Diagn Progn. 2024 (in press).
27. Teramoto Y, Najafi MAE, Matsukawa T, Sharma A, Goto T, Miyamoto H.
Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression.
Int J Mol Sci. 2024 Jul 2;25(13):7289.
28. Teramoto Y, Yang Z, Matsukawa T, Najafi MAE, Goto T, Miyamoto H.
PGC1 α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers. Am J Cancer Res. 2024 Sep 15;14(9):4367-4377.

29. Tatenuma T, Matsukawa T, Goto T, Jiang G, Sharma A, Najafi MAE, Teramoto Y, Miyamoto H.
GULP1 as a Downstream Effector of the Estrogen Receptor- β Modulates Cisplatin Sensitivity in Bladder Cancer.
Cancer Genomics Proteomics. 2024 Nov-Dec;21(6):557-565.

症例報告

1. Tsubonuma Y, Funakoshi K, Takaba T, Jyojima K, Minato A, Tomisaki I, Harada K, Fujimoto N.
Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer
A Report of Four Cases J UOEH. 46(1):23-28, 2024